Appili Therapeutics Inc (APLI) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.018x

Based on the latest financial reports, Appili Therapeutics Inc (APLI) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-293.07K ≈ $-212.00K USD) by net assets (CA$-16.38 Million ≈ $-11.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See APLI equity to assets ratio to measure how much of total assets are equity-financed.

Appili Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Appili Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check APLI cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Appili Therapeutics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Appili Therapeutics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Rajdarshan Industries Limited NSE:ARENTERP	-0.005x
Ucommune International Ltd NASDAQ:UK	-0.019x
Vault Strategic Mining Corp. V:KNOX	0.054x
Macfarlane Group PLC LSE:MACF	0.103x
Univa Foods Limited NSE:UNIVAFOODS	-0.001x
Uniinfo Telecom Services Limited NSE:UNIINFO	0.029x
Mercia Technologies PLC LSE:MERC	0.032x
Valora Effekten Handel AG F:VEH	N/A

Annual Cash Flow Conversion Efficiency for Appili Therapeutics Inc (2017–2025)

The table below shows the annual cash flow conversion efficiency of Appili Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Appili Therapeutics Inc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	CA$-13.40 Million ≈ $-9.69 Million	CA$868.82K ≈ $628.49K	-0.065x	-128.75%
2024-03-31	CA$-10.92 Million ≈ $-7.90 Million	CA$-2.46 Million ≈ $-1.78 Million	0.226x	-83.48%
2023-03-31	CA$-7.40 Million ≈ $-5.35 Million	CA$-10.10 Million ≈ $-7.30 Million	1.365x	-76.60%
2022-03-31	CA$-3.27 Million ≈ $-2.37 Million	CA$-19.08 Million ≈ $-13.80 Million	5.834x	+749.77%
2021-03-31	CA$12.75 Million ≈ $9.23 Million	CA$-11.45 Million ≈ $-8.28 Million	-0.898x	-86.42%
2020-03-31	CA$8.85 Million ≈ $6.40 Million	CA$-4.26 Million ≈ $-3.08 Million	-0.482x	+38.42%
2019-03-31	CA$4.42 Million ≈ $3.20 Million	CA$-3.46 Million ≈ $-2.50 Million	-0.782x	-15.22%
2018-03-31	CA$4.87 Million ≈ $3.52 Million	CA$-3.30 Million ≈ $-2.39 Million	-0.679x	+56.34%
2017-03-31	CA$1.37 Million ≈ $994.41K	CA$-2.14 Million ≈ $-1.55 Million	-1.555x	--

About Appili Therapeutics Inc

TO:APLI Canada Biotechnology

Market Cap

$1.39 Million

CA$1.93 Million CAD

Market Cap Rank

#30334 Global

#1544 in Canada

Share Price

CA$0.02

Change (1 day)

+50.00%

52-Week Range

CA$0.01 - CA$0.04

All Time High

CA$1.87